Kiko Ventures

Kiko Ventures

Kiko Ventures launched in London as a commitment from IP Group, the publicly listed intellectual property commercialization firm, to build a dedicated, flexible capital vehicle for deep-tech and climate innovation. Rather than raising successive funds from external LPs, the firm manages a portfolio constructed from direct balance-sheet allocations, which allows for patient capital deployment across science-heavy sectors. The founding mandate focuses on technologies emerging from university labs and research institutions, particularly those addressing the energy transition and healthcare breakthroughs. The investment strategy spans pre-seed to Series B, targeting companies with demonstrable scientific differentiation. Sector coverage includes clean energy, advanced materials, carbon capture, and precision medicine, with a geographic emphasis on the UK and European ecosystem, though select opportunities in North America and Asia Pacific are considered. The portfolio features companies such as First Light Fusion, which is pursuing inertial confinement fusion for clean power generation, and Hysata, an Australian electrolyzer technology firm aiming to lower the cost of green hydrogen. The firm participates in syndicates alongside other deep-tech specialist investors but does not operate a fund-of-funds model. The IP Group relationship provides Kiko Ventures with structural access to a network of more than 30 university partnerships across the UK, US, and Australasia, feeding a proprietary deal-flow channel that few other venture firms can replicate. While the firm does not publicly disclose its total assets under management or team size, its parent company, IP Group, reported a net asset value of approximately £1.3 billion across its portfolio in late 2023, of which Kiko represents a concentrated subset of early-stage holdings. The firm operates from IP Group's London offices and remains closely integrated with the parent's scientific advisory and IP evaluation resources. Kiko Ventures is structurally distinct from most venture firms because it is not a fund manager raising blind-pool capital. Its permanent-capital vehicle provides the governance freedom to hold equity positions for decades—a critical advantage when commercializing physics-based hardware and biotech platforms that require long development cycles. This architecture sidesteps the typical 10-year fund-life constraint, aligning the firm's incentives with the technology maturation timelines its portfolio companies actually face.